| __timestamp | BioCryst Pharmaceuticals, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 72429000 |
| Thursday, January 1, 2015 | 13047000 | 78634000 |
| Friday, January 1, 2016 | 11253000 | 75374000 |
| Sunday, January 1, 2017 | 13933000 | 92157000 |
| Monday, January 1, 2018 | 29514000 | 93326000 |
| Tuesday, January 1, 2019 | 37121000 | 103132000 |
| Wednesday, January 1, 2020 | 67929000 | 110171000 |
| Friday, January 1, 2021 | 118818000 | 218817000 |
| Saturday, January 1, 2022 | 159371000 | 233827000 |
| Sunday, January 1, 2023 | 213894000 | 267194000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, Lantheus Holdings, Inc. and BioCryst Pharmaceuticals, Inc. have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Lantheus consistently outpaced BioCryst, with SG&A expenses peaking at approximately $267 million in 2023, a 270% increase from 2014. In contrast, BioCryst's expenses grew by a staggering 2,765% over the same period, reaching around $214 million. This divergence highlights Lantheus's steady growth and BioCryst's aggressive expansion strategy. The data underscores the importance of strategic financial management in sustaining competitive advantage. As the industry braces for future challenges, these insights offer a glimpse into the operational priorities of two key players.
Cost Management Insights: SG&A Expenses for Novartis AG and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Genmab A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Genmab A/S vs BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Breaking Down Revenue Trends: Lantheus Holdings, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?